• HOXC8 Suppresses Pyroptosis in NSCLC via Caspase-1 Regulatio

  2026-07-27

  The referenced study uncovers how HOXC8, a homeobox transcription factor, inhibits pyroptotic cell death in non-small cell lung carcinoma (NSCLC) by suppressing caspase-1 expression through HDAC1/2 recruitment. This work reveals a previously unappreciated non-canonical pathway for pyroptosis regulation and highlights new targets for inflammation research and cancer therapy.

• BRCA2 Shields RAD51 Filaments from PARP1 Retention by PARPi

  2026-07-27

  This study uncovers a direct mechanistic link between BRCA2 and PARP inhibitor sensitivity in DNA repair-deficient cells. Using single-molecule and biochemical assays, the authors show that BRCA2 prevents PARPi-induced PARP1 retention at DNA break sites, thereby protecting RAD51 filament stability and homologous recombination repair.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-07-26

  The reference study presents a new class of allosteric pyruvate dehydrogenase kinase 4 (PDK4) inhibitors, notably compound 8c, which demonstrates high potency and metabolic stability. These findings offer a promising avenue for treating metabolic diseases and allergic responses by targeting PDK4-mediated pathways.

• SERPINH1–MMP-9/TGFβ1 Feedback Drives Lung Adenocarcinoma Pro

  2026-07-25

  This study reveals a positive feedback loop between SERPINH1 and MMP-9/TGFβ1 that promotes lung adenocarcinoma (LUAD) proliferation, invasion, and metastasis. By uncovering the mechanistic basis of stromal cell activation and CAF transformation, the work identifies SERPINH1 as a potential prognostic and therapeutic target, offering insights for future translational research.

• 5-Aminolevulinic Acid HCl: Unraveling Heme Synthesis and Imm

  2026-07-24

  Explore the multifaceted roles of 5-Aminolevulinic acid HCl in heme biosynthesis and bacterial immune evasion. This article delivers advanced insights beyond standard protocols, integrating the latest mechanistic findings and guiding assay optimization for innovative cancer and infection research.

• Rhodamine B: Protocol Enhancements for Precision Cell Labeli

  2026-07-24

  Rhodamine B (Basic Violet 10) stands out as a high-purity fluorescent probe, optimizing workflows from cell labeling to quantitative fluorescence assays. Explore practical protocols, troubleshooting, and advanced use-cases leveraging its remarkable solubility and signal fidelity.

• Hypoxia and Immunometabolism in the Tumor Microenvironment

  2026-07-23

  This review dissects how hypoxia-driven metabolic reprogramming and immune cell adaptations shape the tumor microenvironment, fostering immunosuppression and supporting tumor progression. By clarifying the mechanistic interplay between oxygen deprivation, nutrient competition, and altered immune function, the study points toward new avenues for metabolism-based tumor therapies.

• GPR30 in Spinal CCK+ Neurons: A Modulator of Neuropathic Pai

  2026-07-23

  This study reveals that GPR30, a membrane estrogen receptor, is upregulated in spinal cholecystokinin-positive (CCK+) neurons during neuropathic pain and critically modulates pain sensitivity via synaptic mechanisms. These findings identify GPR30 as a pivotal target for therapeutic intervention in neuropathic pain states.

• Connexin 43/NF-κB Pathway in AngII-Induced Macrophage Polari

  2026-07-22

  This study elucidates how angiotensin II (AngII) drives RAW264.7 macrophages toward an M1 pro-inflammatory state via the connexin 43/NF-κB axis. By employing connexin 43 mimetic peptides such as Gap26, the work demonstrates a mechanistic link between gap junction signaling and macrophage-mediated inflammation, with implications for atherosclerosis and vascular research.

• Verteporfin as a Molecular Glue Activator of IRE1α in Breast

  2026-07-22

  Liu et al. reveal that verteporfin functions as a molecular glue, inducing IRE1α dimerization and activation in breast cancer cells. This mechanistic insight not only establishes a novel link between the unfolded protein response and PI3K/AKT signaling but also demonstrates that combining verteporfin with AKT inhibitors offers enhanced therapeutic potential against aggressive breast cancer subtypes.

• Griseofulvin in Translational Research: Microtubule Insights

  2026-07-21

  Explore how Griseofulvin, a microtubule associated inhibitor, drives precision in fungal mitosis research and aneugenicity mechanism elucidation. This thought-leadership article bridges molecular insight, experimental best practices, and translational strategy—drawing on recent mechanistic assays, current literature, and APExBIO’s product intelligence—to guide researchers toward rigorous, innovative antifungal and genomic stability studies.

• Next-Gen Cell Proliferation: EdU Imaging Kits (Cy5) in Trans

  2026-07-21

  Explore the mechanistic, strategic, and translational advances enabled by EdU Imaging Kits (Cy5). This article bridges cutting-edge cell cycle S-phase DNA synthesis measurement with critical biological models—such as ovarian granulosa cell fate—offering practical protocol insights and visionary guidance for researchers aiming to accelerate discovery in genotoxicity, pharmacodynamics, and regenerative medicine.

• Deferasirox Impacts Myeloid Differentiation via NF-κB and Mi

  2026-07-20

  This study reveals that Deferasirox, a clinically used iron chelator, modulates myeloid differentiation through stage-specific effects on mitochondrial reactive oxygen species and NF-κB pathway activity. These findings clarify the non-linear relationship between iron chelation, oxidative signaling, and hematopoietic cell fate, with implications for both iron overload treatment research and the biology of myelodysplastic syndromes.

• Ferrostatin-1 (Fer-1): Optimizing Ferroptosis Assays in Dise

  2026-07-20

  Ferrostatin-1 (Fer-1) empowers researchers to dissect ferroptosis in cancer, neurodegeneration, and inflammatory settings with nanomolar precision. This article details experimental workflows, troubleshooting strategies, and protocol optimizations grounded in the latest mechanistic and translational insights.

• Dissecting Drug Responses in Cancer: Insights from In Vitro

  2026-07-19

  Schwartz's dissertation addresses a critical gap in cancer pharmacology by distinguishing between proliferation arrest and cell death in drug response assays. Her work introduces a refined analytical framework that improves the precision of in vitro evaluation of anti-cancer agents, with implications for experimental design and interpretation in cancer chemotherapy research.

15087 records 1/1006 page Next 12345 下5页 Last page